Infliximab, a chimeric (humanized mouse) monoclonal antibody which specifically inhibits TNF-alpha, has recently shown efficacy in the treatment of refractory sarcoidosis. The manifestations of sarcoidosis are diverse; however, the long-term effects on the lungs are often the most life-threatening. We describe a patient with sarcoidosis who experienced the complete resolution of her cutaneous disease and stabilization of her pulmonary symptoms after initiation of infliximab.
|Original language||English (US)|
|Number of pages||2|
|Journal||Journal of drugs in dermatology : JDD|
|State||Published - Aug 2003|
ASJC Scopus subject areas